Address: 12 Rose & Crown Walk
Saffron Walden
Essex CB10 1JH, U.K
Tel: +44 1799 513391
Web: http://www.atlantichc.com/
Atlantic Healthcare Ltd is the holding company for a healthcare group supplying products for the treatment of patients under the management of hospital-based specialists, principally in the United States and Europe.
Atlantic Healthcare is acquiring companies and products for distribution via its hospital sales channel, that have the potential for peak sales of up to £250m ($400m) that are normally too small to be of interest to major pharmaceutical and healthcare groups.
The management team and Board consists of experienced senior executives with deep knowledge of and extensive networks within the pharmaceutical industry and hospital sector, including Elan Pharmaceuticals, Eli Lilly, Glaxo, Novartis, Pfizer, RPR, SmithKline Beecham and Wyeth. The team and Board have a track record of successful private and public-sector company building.
In March 2007, Atlantic Healthcare signed an exclusive licensing agreement with Isis Pharmaceuticals, Inc (NASDAQ:ISIS) in which it acquired the global rights to late-stage anti-inflammatory, antisense drug programmes
Atlantic Healthcare’s acquired clinical programmes for alicaforsen target inflammatory bowel diseases. Clinical data on alicaforsen used in these programmes, demonstrates significant safety, efficacy, tolerability and durability benefits, with the potential for clear and strong product differentiation
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
See our Cookie Privacy Policy Here
